Isbn: 9783030719159 - chronic myeloid leukemia (9 risultati)

Perfeziona la tua ricerca

  • Libri (9)

  • Nuovo (9)

a

Fascia di prezzo personalizzata (EUR)

a

    • Lingua: Inglese

      Editore: Springer, 2022

      3030719154 / 9783030719159

      Serie: Libro 15 di 15 - Hematologic Malignancies

      • Brossura

      Da: Books Puddle, New York, NY, U.S.A.Books Puddle

      Venditore con 4 stelle
      Contatta il venditore

      Condizione: Nuovo

      EUR 122,40

      EUR 3,43 spedizione 
      Spedito in U.S.A.

      Quantità: 4 disponibili

      Condizione: New. 2nd ed. 2021 edition NO-PA16APR2015-KAP.

    • Lingua: Inglese

      Editore: Springer, 2022

      3030719154 / 9783030719159

      Serie: Libro 15 di 15 - Hematologic Malignancies

      • Brossura

      Da: AHA-BUCH GmbH, Einbeck, GermaniaAHA-BUCH GmbH

      Venditore con 5 stelle
      Contatta il venditore

      Condizione: Nuovo

      EUR 93,36

      EUR 30,50 spedizione 
      Spedito da Germania a U.S.A.

      Quantità: 1 disponibili

      Taschenbuch. Condizione: Neu. Druck auf Anfrage Neuware - Printed after ordering - This book provides state-of-the-art reviews of key issues and recent developments relating to chronic myeloid leukemia (CML), acquainting the reader with advances in research, treatment, and promotion of public health. Among the management topics addressed are the choices, advantages, and pitfalls of first-, second-, and third-line treatments; the European LeukemiaNet recommendations; management of adverse effects of tyrosine kinase inhibitors (TKI); management of CML blast crisis; management of pregnancy in the context of CML; the role of hematopoietic cell transplantation; the current experience with TKI discontinuation; and the value of interferon in improving the outcome of TKI treatment. Various aspects of relevance to treatment outcome are discussed, including prognostic scores, molecular monitoring (principles and interlaboratory standardization), and response-related predictors of survival. Furthermore, updates are provided on the increasing prevalence of CML and its implications and on the changing cost of care for CML, taking into account the impact of availability of generic imatinib.

    • Lingua: Inglese

      Editore: Springer, 2022

      3030719154 / 9783030719159

      Serie: Libro 15 di 15 - Hematologic Malignancies

      • Brossura

      Da: preigu, Osnabrück, Germaniapreigu

      Venditore con 5 stelle
      Contatta il venditore

      Condizione: Nuovo

      EUR 77,35

      EUR 70,00 spedizione 
      Spedito da Germania a U.S.A.

      Quantità: 5 disponibili

      Taschenbuch. Condizione: Neu. Chronic Myeloid Leukemia | Rüdiger Hehlmann | Taschenbuch | Hematologic Malignancies | ix | Englisch | 2022 | Springer | EAN 9783030719159 | Verantwortliche Person für die EU: Springer Verlag GmbH, Tiergartenstr. 17, 69121 Heidelberg, juergen[dot]hartmann[at]springer[dot]com | Anbieter: preigu.

    • Lingua: Inglese

      Editore: Springer International Publishing, Springer Nature Switzerland Jun 2022, 2022

      3030719154 / 9783030719159

      Serie: Libro 15 di 15 - Hematologic Malignancies

      • Brossura
      • Print on Demand

      Da: BuchWeltWeit Ludwig Meier e.K., Bergisch Gladbach, GermaniaBuchWeltWeit Ludwig Meier e.K.

      Venditore con 5 stelle
      Contatta il venditore

      Condizione: Nuovo

      EUR 42,79

      EUR 23,00 spedizione 
      Spedito da Germania a U.S.A.

      Quantità: 1 disponibili

      Taschenbuch. Condizione: Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -This book provides state-of-the-art reviews of key issues and recent developments relating to chronic myeloid leukemia (CML), acquainting the reader with advances in research, treatment, and promotion of public health. Among the management topics addressed are the choices, advantages, and pitfalls of first-, second-, and third-line treatments; the European LeukemiaNet recommendations; management of adverse effects of tyrosine kinase inhibitors (TKI); management of CML blast crisis; management of pregnancy in the context of CML; the role of hematopoietic cell transplantation; the current experience with TKI discontinuation; and the value of interferon in improving the outcome of TKI treatment. Various aspects of relevance to treatment outcome are discussed, including prognostic scores, molecular monitoring (principles and interlaboratory standardization), and response-related predictors of survival. Furthermore, updates are provided on the increasing prevalence of CML and its implications and on the changing cost of care for CML, taking into account the impact of availability of generic imatinib. 284 pp. Englisch.

    • Lingua: Inglese

      Editore: Springer, 2022

      3030719154 / 9783030719159

      Serie: Libro 15 di 15 - Hematologic Malignancies

      • Brossura
      • Print on Demand

      Da: Brook Bookstore On Demand, Napoli, NA, ItaliaBrook Bookstore On Demand

      Venditore con 5 stelle
      Contatta il venditore

      Condizione: Nuovo

      EUR 70,24

      EUR 6,80 spedizione 
      Spedito da Italia a U.S.A.

      Quantità: Più di 20 disponibili

      Condizione: new. Questo è un articolo print on demand.

    • Lingua: Inglese

      Editore: Springer International Publishing, 2022

      3030719154 / 9783030719159

      Serie: Libro 15 di 15 - Hematologic Malignancies

      • Brossura
      • Print on Demand

      Da: moluna, Greven, Germaniamoluna

      Venditore con 5 stelle
      Contatta il venditore

      Condizione: Nuovo

      EUR 72,89

      EUR 48,99 spedizione 
      Spedito da Germania a U.S.A.

      Quantità: Più di 20 disponibili

      Kartoniert / Broschiert. Condizione: New. Dieser Artikel ist ein Print on Demand Artikel und wird nach Ihrer Bestellung fuer Sie gedruckt. Presents state-of-the-art reviews of key issues relating to chronic myeloid leukemiaCovers a wide range of management topicsDiscusses prognostic aspects and early response predictionExamines the changing face and cost of care.

    • Lingua: Inglese

      Editore: Springer, 2022

      3030719154 / 9783030719159

      Serie: Libro 15 di 15 - Hematologic Malignancies

      • Brossura
      • Print on Demand

      Da: Majestic Books, Hounslow, Regno UnitoMajestic Books

      Venditore con 4 stelle
      Contatta il venditore

      Condizione: Nuovo

      EUR 123,59

      EUR 7,57 spedizione 
      Spedito da Regno Unito a U.S.A.

      Quantità: 4 disponibili

      Condizione: New. Print on Demand.

    • Lingua: Inglese

      Editore: Springer, 2022

      3030719154 / 9783030719159

      Serie: Libro 15 di 15 - Hematologic Malignancies

      • Brossura
      • Print on Demand

      Da: Biblios, frankfurt am main, HESSE, GermaniaBiblios

      Venditore con 4 stelle
      Contatta il venditore

      Condizione: Nuovo

      EUR 125,63

      EUR 9,95 spedizione 
      Spedito da Germania a U.S.A.

      Quantità: 4 disponibili

      Condizione: New. PRINT ON DEMAND.

    • Lingua: Inglese

      Editore: Springer, Springer Jun 2022, 2022

      3030719154 / 9783030719159

      Serie: Libro 15 di 15 - Hematologic Malignancies

      • Brossura
      • Print on Demand

      Da: buchversandmimpf2000, Emtmannsberg, BAYE, Germaniabuchversandmimpf2000

      Venditore con 5 stelle
      Contatta il venditore

      Condizione: Nuovo

      EUR 85,59

      EUR 60,00 spedizione 
      Spedito da Germania a U.S.A.

      Quantità: 1 disponibili

      Taschenbuch. Condizione: Neu. This item is printed on demand - Print on Demand Titel. Neuware -This book provides state-of-the-art reviews of key issues and recent developments relating to chronic myeloid leukemia (CML), acquainting the reader with advances in research, treatment, and promotion of public health. Among the management topics addressed are the choices, advantages, and pitfalls of first-, second-, and third-line treatments; the European LeukemiaNet recommendations; management of adverse effects of tyrosine kinase inhibitors (TKI); management of CML blast crisis; management of pregnancy in the context of CML; the role of hematopoietic cell transplantation; the current experience with TKI discontinuation; and the value of interferon ¿ in improving the outcome of TKI treatment. Various aspects of relevance to treatment outcome are discussed, including prognostic scores, molecular monitoring (principles and interlaboratory standardization), and response-related predictors of survival. Furthermore, updates are provided on the increasing prevalence of CML and its implications and on the changing cost of care for CML, taking into account the impact of availability of generic imatinib.Springer-Verlag KG, Sachsenplatz 4-6, 1201 Wien 284 pp. Englisch.